Capstone Therapeutics Corp. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2016. The provided filing identifies the registrant as Capstone Therapeutics Corp., although the request metadata names Capstone Holding Corp. The financial statements are unaudited and consolidate the Company and its 64%-owned subsidiary, LipimetiX Development, Inc.
Business Context
The Company is a biotechnology development-stage business operating under a virtual model. Its principal program is AEM-28 and the prioritized analog AEM-28-14, being developed through LipimetiX for hyperlipidemia and related indications. Earlier programs, including Chrysalin and AZX100, have been discontinued or returned to licensors. The Company has no revenue-producing operations and has reported a substantial doubt regarding its ability to continue as a going concern.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2016 | Three Months Ended June 30, 2015 | Six Months Ended June 30, 2016 | Six Months Ended June 30, 2015 |
|---|---|---|---|---|
| General and administrative expense | $157 thousand | $552 thousand | $382 thousand | $1.024 million |
| Research and development expense | $220 thousand | $283 thousand | $377 thousand | $633 thousand |
| Total operating expenses | $377 thousand | $835 thousand | $759 thousand | $1.657 million |
| Net loss | $390 thousand | $752 thousand | $769 thousand | $1.468 million |
| Net loss per share | $0.01 | $0.02 | $0.02 | $0.04 |
Revenue and margins: No revenue was reported. Gross margin and operating margin are not meaningful because the Company has no revenue-producing operations.
Cash flow: Cash used in operating activities was $319 thousand for the first six months of 2016, compared with $1.127 million in the prior-year period. There were no investing or financing cash flows reported. Cash and cash equivalents declined from $1.011 million at December 31, 2015 to $692 thousand at June 30, 2016.
Balance sheet and liquidity: Total assets were $1.200 million, including $431 thousand of net patent license rights. Current liabilities were $431 thousand, and the Company had $1.000 million of convertible promissory notes payable. Total equity was negative $231 thousand, compared with positive equity of $506 thousand at year-end 2015. The Company had loaned $1.553 million to the joint venture, exceeding the stated $1.500 million net revolving-loan limit described in the filing.
Material Changes Versus Prior Comparable Period
- First-half net loss decreased by $699 thousand, or approximately 48%, primarily due to reduced operating activity and cost-cutting measures.
- First-half G&A expense declined approximately 63% due to reduced salary and consulting rates, lower professional fees and insurance costs, and reduced fundraising expenses.
- First-half R&D expense declined approximately 40% as development activities were significantly curtailed while the Company sought funding.
- Second-quarter R&D included a $125 thousand purchase of drug material for future preclinical testing.
- Cash declined $319 thousand during the first half, although the decline was substantially lower than the $1.127 million decrease in the prior-year period.
- On March 31, 2016, the Company converted 1.5 million preferred shares in the joint venture into 120,000 common shares, increasing its stated ownership from 60% to 64%.
- Effective June 1, 2016, new joint venture management and accounting services agreements provided for monthly fees of approximately $80 thousand and $10 thousand, respectively; no management fee was owed at June 30, 2016, because payment is funding-dependent and subject to approval.
Guidance, Outlook, Risks, and Unusual Items
- Management stated that the Company and joint venture do not have sufficient funding for additional material development activities or continued operations. Additional capital is expected to be required within the next 12 months.
- Potential funding sources include strategic or merger transactions, debt or equity offerings, partnering, licensing, joint-development arrangements, or sales of development rights. Availability and terms are uncertain and could materially dilute existing stockholders.
- The $1.000 million convertible notes bear 5% interest, are secured by substantially all Company assets, and mature April 30, 2017 unless converted. Lenders may elect conversion within specified price limits, and they collectively owned approximately 19% of the Company’s common stock.
- The joint venture’s initial Phase 1a and Phase 1b/2a studies were completed in 2014 with a generally acceptable safety profile and favorable exploratory biomarker results, but further development depends on funding, regulatory approvals, and partnering.
- The Company did not engage an independent public accountant to audit its 2015 annual financial statements or review this Form 10-Q. Management stated that this may result in SEC or OTCQB action and could adversely affect the Company and trading in its common stock.
- The filing states that the Company’s prior audit report included substantial doubt about going-concern viability. The current financial statements do not reflect adjustments that could result from the uncertainty over obtaining funding.
- If the joint venture cannot continue as a going concern, the Company could incur an additional loss of $667 thousand related to losses allocated to noncontrolling interests.
- The filing reports no material legal proceedings and states that management concluded its disclosure controls were effective as of June 30, 2016.
Investor Verification Items
- Verify the registrant’s correct legal name and ticker, given the discrepancy between the request metadata and the filing text.
- Assess near-term liquidity, cash burn, and the feasibility and timing of additional financing.
- Review the terms, conversion mechanics, security interests, and maturity of the $1.000 million convertible notes.
- Reconcile the $1.553 million of joint venture advances with the stated $1.500 million revolving-loan limit and evaluate recoverability.
- Confirm the impact of the unaudited filing and lack of independent accountant review on SEC compliance, OTCQB quotation, and trading liquidity.
- Evaluate the status, funding requirements, regulatory pathway, patent protection, and clinical evidence for AEM-28-14.